Vyleesi, Imcivree (bremelanotide) is a protein pharmaceutical. Bremelanotide was first approved as Vyleesi on 2019-06-21. It has been approved in Europe to treat obesity. It is known to target melanocyte-stimulating hormone receptor, melanocortin receptor 5, melanocortin receptor 4, and melanocortin receptor 3. Vyleesi's patents are valid until 2033-11-05 (FDA).
|Drug Class||Peptides: melanocortin receptor antagonists|